{"id":"W4282977080","doi":"10.1158/1538-7445.am2022-ct035","title":"Abstract CT035: Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université du Québec; William Osler Health System; Université Laval","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Cyclophosphamide; Cancer; Oncology; Immunotherapy; Survivin; Bladder cancer; CD8; Immune system; Chemotherapy; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004109847,0.0003685322,0.000622825,0.0001863267,0.0002474902,0.0003642267,0.0002582661,0.0003613566,0.001556732],"category_scores_gemma":[0.0004986466,0.0001512371,0.0003147682,0.0002375191,0.0002630775,0.0002209223,0.0001163383,0.0006923486,0.0002888198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000550397,"about_ca_system_score_gemma":0.0005423628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001051507,"about_ca_topic_score_gemma":0.00157497,"domain_scores_codex":[0.9998155,0.00006957148,0.00001684168,0.00003383924,0.00003252779,0.00003176884],"domain_scores_gemma":[0.9997223,0.00005697304,0.00006461866,0.00001887775,0.00002541854,0.000111887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2730265,0.01837676,0.1325417,0.000655014,0.0009774192,0.001283199,0.0004845937,0.002883978,0.3263133,0.0001883149,0.003091142,0.2401781],"study_design_scores_gemma":[0.02691805,0.5568122,0.3370842,0.00006432044,0.000950043,0.00300115,0.0001463411,0.004835804,0.06396699,0.00008406217,0.006093929,0.00004287481],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982873,0.0007322591,0.0001504807,0.00004335689,0.00000798828,0.00007917928,0.000162519,0.00002041708,0.0005166],"genre_scores_gemma":[0.9989831,0.0001337134,0.0001717667,0.0000500483,0.00001599231,0.00005188708,0.0003126987,0.000002664165,0.0002781966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001556732,"threshold_uncertainty_score":0.005207777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01755569767508987,"score_gpt":0.3322421358152522,"score_spread":0.3146864381401623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}